ICYMI – Where’s Robert Stack When You Need Him?
ICYMI May 5, 2015 The New York Times: Runaway Drug Prices How companies set… Read More
ICYMI May 5, 2015 The New York Times: Runaway Drug Prices How companies set… Read More
April 28, 2015 Note: Distributing the New York Times article below is not an… Read More
Two-fer ICYMI: Two WSJ Articles Highlight High Drug… Read More
Originally published on AmericanPharmacyNews.com. Read More
Are Skyrocketing Drug Prices Really Needed for Innovation? Amgen’s… Read More
This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.” Read More
Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex ($VRTX) will stir the pot when its new cystic fibrosis combo--expected to win FDA approval later this year--hits the market. But just how much will payers need to shell out for the new med over time? Prime Therapeutics has some ideas. Read More
Drug retail giant CVS Health Corp. is girding to do battle with pharmaceutical companies over a coming class of cholesterol drugs that CVS says could cost the nation’s health-care system $150 billion a year. Read More
Ever since Obamacare took effect, Republicans have warned of mission creep: that a law bringing more government regulation to health care would eventually morph into single-payer. Read More
A national group of more than 140,000 physicians on Tuesday joined a coalition dedicated to reversing the growing trend of high-cost specialty drugs, which are being blamed for straining the finances of patients, insurance plans and public health coverage programs. Read More
The Obama administration’s fiscal 2016 budget request calls for allowing the government to negotiate the price of prescription drugs and giving regulators new funding to fight Ebola. Read More
The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs. Read More